RATIONALE: We have proposed rewarded T-maze alternation as a model of obsessive-compulsive disorder (OCD): the serotonin agonist m-chlorophenylpiperazine (mCPP) increments persistence therein, while chronic pretreatment with selective serotonin reuptake inhibitor (SSRI fluoxetine) but not benzodiazepine or desipramine abolishes mCPP effects. However, we noted that acute SSRI administration also causes transient persistence increase, counteracted by mCPP pretreatment. OBJECTIVES: This study (a) further explores the cross-tolerance between fluoxetine and mCPP and (b) extends the model by investigating its sensitivity to dopaminergic manipulations (D2, 3 agonism--quinpirole). MATERIALS AND METHODS: In both experiments, baseline and drug testing were carried out under daily T-maze alternation training. Exp. 1: Matched group (n = 8) pairs of rats received one of the following 20-day pretreatments (daily intraperitoneal administration): (1) saline, (2) low-dose fluoxetine (2.5 mg/kg), (3) low-dose mCPP (0.5 mg/kg) or (4) combined fluoxetine + mCPP. One group per pretreatment then received a 4-day challenge with high-dose fluoxetine (10 mg/kg), the other with high-dose mCPP (2.5 mg/kg). Exp. 2: One group (n = 12) of rats received 20-day treatment with saline, another with quinpirole (0.5 mg/kg). RESULTS: Exp. 1: Saline and low-dose mCPP- or fluoxetine-pretreated animals showed significant persistence increases under both challenges, while combined low-dose fluoxetine + mCPP pretreatment afforded full protection from either challenge. Exp. 2: Quinpirole significantly increased directional persistence after 13 administration days. CONCLUSIONS: These results establish the sensitivity of the rewarded alternation OCD model to D2, 3 receptor activation, thereby extending its profile of pharmacological isomorphism with OCD. Furthermore, they suggest a common mechanism of action of an SSRI and a serotonin agonist in the control of directional persistence.
RATIONALE: We have proposed rewarded T-maze alternation as a model of obsessive-compulsive disorder (OCD): the serotonin agonist m-chlorophenylpiperazine (mCPP) increments persistence therein, while chronic pretreatment with selective serotonin reuptake inhibitor (SSRI fluoxetine) but not benzodiazepine or desipramine abolishes mCPP effects. However, we noted that acute SSRI administration also causes transient persistence increase, counteracted by mCPP pretreatment. OBJECTIVES: This study (a) further explores the cross-tolerance between fluoxetine and mCPP and (b) extends the model by investigating its sensitivity to dopaminergic manipulations (D2, 3 agonism--quinpirole). MATERIALS AND METHODS: In both experiments, baseline and drug testing were carried out under daily T-maze alternation training. Exp. 1: Matched group (n = 8) pairs of rats received one of the following 20-day pretreatments (daily intraperitoneal administration): (1) saline, (2) low-dose fluoxetine (2.5 mg/kg), (3) low-dose mCPP (0.5 mg/kg) or (4) combined fluoxetine + mCPP. One group per pretreatment then received a 4-day challenge with high-dose fluoxetine (10 mg/kg), the other with high-dose mCPP (2.5 mg/kg). Exp. 2: One group (n = 12) of rats received 20-day treatment with saline, another with quinpirole (0.5 mg/kg). RESULTS: Exp. 1: Saline and low-dose mCPP- or fluoxetine-pretreated animals showed significant persistence increases under both challenges, while combined low-dose fluoxetine + mCPP pretreatment afforded full protection from either challenge. Exp. 2: Quinpirole significantly increased directional persistence after 13 administration days. CONCLUSIONS: These results establish the sensitivity of the rewarded alternation OCD model to D2, 3 receptor activation, thereby extending its profile of pharmacological isomorphism with OCD. Furthermore, they suggest a common mechanism of action of an SSRI and a serotonin agonist in the control of directional persistence.
Authors: R Hoehn-Saric; P Ninan; D W Black; S Stahl; J H Greist; B Lydiard; S McElroy; J Zajecka; D Chapman; C Clary; W Harrison Journal: Arch Gen Psychiatry Date: 2000-01
Authors: J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft Journal: J Pharmacol Exp Ther Date: 1998-08 Impact factor: 4.030
Authors: W K Goodman; L H Price; P L Delgado; J Palumbo; J H Krystal; L M Nagy; S A Rasmussen; G R Heninger; D S Charney Journal: Arch Gen Psychiatry Date: 1990-06
Authors: E Hollander; C DeCaria; R Gully; A Nitescu; R F Suckow; J M Gorman; D F Klein; M R Liebowitz Journal: Psychiatry Res Date: 1991-01 Impact factor: 3.222
Authors: W K Goodman; C J McDougle; L H Price; L C Barr; O F Hills; J F Caplik; D S Charney; G R Heninger Journal: Biol Psychiatry Date: 1995-08-01 Impact factor: 13.382
Authors: Marco Bortolato; Kevin Chen; Sean C Godar; Gao Chen; Weihua Wu; Igor Rebrin; Mollee R Farrell; Anna L Scott; Cara L Wellman; Jean C Shih Journal: Neuropsychopharmacology Date: 2011-08-10 Impact factor: 7.853
Authors: Mark C Tucci; Anna Dvorkin-Gheva; Dawn Graham; Sean Amodeo; Paul Cheon; Ashley Kirk; John Peel; Leena Taji; Henry Szechtman Journal: Psychopharmacology (Berl) Date: 2013-01-25 Impact factor: 4.530
Authors: Hana Hatalova; Dominika Radostova; Adela Pistikova; Karel Vales; Ales Stuchlik Journal: Front Behav Neurosci Date: 2014-04-11 Impact factor: 3.558
Authors: Mélanie Lagière; Marion Bosc; Sara Whitestone; Abdelhamid Benazzouz; Abdeslam Chagraoui; Mark J Millan; Philippe De Deurwaerdère Journal: Int J Mol Sci Date: 2020-11-12 Impact factor: 5.923